Horizon scanning: Aflibercept (EYLEA) approved for the treatment of wet age-related macular degeneration in Australia

Source: PharmaTimes
Area: News
PharmaTimes reports that the Australian regulatory authority (the Therapeutic Goods Administration - TGA) has approved EYLEA® (aflibercept) injection for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD) at a recommended dose of 2 milligrams via intravitreal injection per month for three consecutive months, followed by 2 milligrams via intravitreal injection every two months. According to PharmaTimes, the company plan to launch the drug in Australia in the second half of 2012.   A marketing authorisation application for aflibercept for the treatment of (Read more...)

Full Story →